Overexpression of YWHAZ relates to tumor cell proliferation and malignant outcome of gastric carcinoma

British Journal of Cancer

Volumn 108, Issue 6, 2013, Pages 1324-1331

  Nishimura, Y ^a   Komatsu, S ^a   Ichikawa, D ^a   Nagata, H ^a   Hirajima, S ^a   Takeshita, H ^a   Kawaguchi, T ^a   Arita, T ^a   Konishi, H ^a   Kashimoto, K ^a   Shiozaki, A ^a   Fujiwara, H ^a   Okamoto, K ^a   Tsuda, H ^b   Otsuji, E ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA 375;

ARTICLE; CANCER CELL CULTURE; CANCER INVASION; CANCER RECURRENCE; CANCER SIZE; CELL PROLIFERATION; GENE; HISTOPATHOLOGY; HOSPITAL; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPH NODE METASTASIS; PRIMARY TUMOR; PRIORITY JOURNAL; STOMACH CARCINOMA; TUMOR GENE; YWHAZ GENE;

14-3-3 PROTEINS; ADULT; AGED; AGED, 80 AND OVER; APOPTOSIS; BLOTTING, WESTERN; CELL ADHESION; CELL MOVEMENT; CELL PROLIFERATION; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION PROFILING; HUMANS; IMMUNOENZYME TECHNIQUES; LYMPHATIC METASTASIS; MALE; MICRORNAS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; STOMACH NEOPLASMS; SURVIVAL RATE; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 84876408821     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.65     Document Type: Article

References (41)

1. Aitken A (2006) 14-3-3 proteins: a historic overview. Semin Cancer Biol 16(3): 162-172.
2. Arora S, Matta A, Shukla NK, Deo SV, Ralhan R (2005) Identification of differentially expressed genes in oral squamous cell carcinoma. Mol Carcinog 42(2): 97-108.
3. Bajpai U, Sharma R, Kausar T, Dattagupta S, Chattopadhayay TK, Ralhan R (2008) Clinical significance of 14-3-3 zeta in human esophageal cancer. Int J Biol Markers 23(4): 231-237.
4. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Ruschoff J, Kang YK (2010) Trastuzumab in combination with chemotherapy vs chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376(9742): 687-697.
5. Becker KF, Atkinson MJ, Reich U, Becker I, Nekarda H, Siewert JR, Hofler H (1994) E-cadherin gene mutations provide clues to diffuse type gastric carcinomas. Cancer Res 54(14): 3845-3852.
6. Danes CG, Wyszomierski SL, Lu J, Neal CL, Yang W, Yu D (2008) 14-3-3 zeta down-regulates p53 in mammary epithelial cells and confers luminal filling. Cancer Res 68(6): 1760-1767.
7. Ding Y, Le XP, Zhang QX, Du P (2003) Methylation and mutation analysis of p16 gene in gastric cancer. World J Gastroenterol 9(3): 423-426.
8. Fan T, Li R, Todd NW, Qiu Q, Fang HB, Wang H, Shen J, Zhao RY, Caraway NP, Katz RL, Stass SA, Jiang F. (2007) Up-regulation of 14-3-3zeta in lung cancer and its implication as prognostic and therapeutic target. Cancer Res 67(16): 7901-7906.
9. Fang DC, Wang RQ, Yang SM, Yang JM, Liu HF, Peng GY, Xiao TL, Luo YH (2003) Mutation and methylation of hMLH1 in gastric carcinomas with microsatellite instability. World J Gastroenterol 9(4): 655-659.
10. Frasor J, Chang EC, Komm B, Lin CY, Vega VB, Liu ET, Miller LD, Smeds J, Bergh J, Katzenellenbogen BS (2006) Gene expression preferentially regulated by tamoxifen in breast cancer cells and correlations with clinical outcome. Cancer Res 66(14): 7334-7340.
11. Garnis C, Coe BP, Ishkanian A, Zhang L, Rosin MP, Lam WL (2004) Novel regions of amplification on 8q distinct from the MYC locus and frequently altered in oral dysplasia and cancer. Genes Chromosomes Cancer 39(1): 93-98.
12. Komatsu S, Imoto I, Tsuda H, Kozaki KI, Muramatsu T, Shimada Y, Aiko S, Yoshizumi Y, Ichikawa D, Otsuji E, Inazawa J (2009) Overexpression of SMYD2 relates to tumor cell proliferation and malignant outcome of esophageal squamous cell carcinoma. Carcinogenesis 30(7): 1139-1146.
13. Lee JH, Abraham SC, Kim HS, Nam JH, Choi C, Lee MC, Park CS, Juhng SW, Rashid A, Hamilton SR, Wu TT (2002) Inverse relationship between APC gene mutation in gastric adenomas and development of adenocarcinoma. Am J Pathol 161(2): 611-618.
14. Li Y, Zou L, Li Q, Haibe-Kains B, Tian R, Li Y, Desmedt C, Sotiriou C, Szallasi Z, Iglehart JD, Richardson AL, Wang ZC (2010) Amplification of LAPTM4B and YWHAZ contributes to chemotherapy resistance and recurrence of breast cancer. Nat Med 16(2): 214-218.
15. Li Z, Zhao J, Du Y, Park HR, Sun SY, Bernal-Mizrachi L, Aitken A, Khuri FR, Fu H (2008) Down-regulation of 14-3-3zeta suppresses anchorageindependent growth of lung cancer cells through anoikis activation. Proc Natl Acad Sci USA 105(1): 162-167.
16. Lu B, Xu J, Zhu Y, Zhang H, Lai M (2007) Systemic analysis of the differential gene expression profile in a colonic adenoma-normal SSH library. Clin Chim Acta 378(1-2): 42-47.
17. Lu J, Guo H, Treekitkarnmongkol W, Li P, Zhang J, Shi B, Ling C, Zhou X, Chen T, Chiao PJ, Feng X, Seewaldt VL, Muller WJ, Sahin A, Hung MC, Yu D (2009) 14-3-3zeta cooperates with ErbB2 to promote ductal carcinoma in situ progression to invasive breast cancer by inducing epithelial-mesenchymal transition. Cancer cell 16 3: 195-207.
18. Maesawa C, Tamura G, Suzuki Y, Ogasawara S, Sakata K, Kashiwaba M, Satodate R (1995) The sequential accumulation of genetic alterations characteristic of the colorectal adenoma-carcinoma sequence does not occur between gastric adenoma and adenocarcinoma. J Pathol 176(3): 249-258.
19. Martin 2nd RC, Jaques DP, Brennan MF, Karpeh M (2002) Extended local resection for advanced gastric cancer: increased survival vs increased morbidity. Ann Surg 236(2): 159-165.
20. Matta A, Bahadur S, Duggal R, Gupta SD, Ralhan R (2007) Over-expression of 14-3-3zeta is an early event in oral cancer. BMC Cancer 7: 169.
21. Matta A, DeSouza LV, Shukla NK, Gupta SD, Ralhan R, Siu KW (2008) Prognostic significance of head-and-neck cancer biomarkers previously discovered and identified using iTRAQ-labeling and multidimensional liquid chromatography-tandem mass spectrometry. J Proteome Res 7(5): 2078-2087.
22. Moore BW, Perez VJ, Gehring M (1968) Assay and regional distribution of a soluble protein characteristic of the nervous system. J Neurochem 15(4): 265-272.
23. Morrison DK (2009) The 14-3-3 proteins: integrators of diverse signaling cues that impact cell fate and cancer development. Trends Cell Biol 19(1): 16-23.
24. Naoi Y, Miyoshi Y, Taguchi T, Kim SJ, Arai T, Maruyama N, Tamaki Y, Noguchi S (2008) Connexin26 expression is associated with aggressive phenotype in human papillary and follicular thyroid cancers. Cancer Lett 262(2): 248-256.
25. Neal CL, Yao J, Yang W, Zhou X, Nguyen NT, Lu J, Danes CG, Guo H, Lan KH, Ensor J, Hittelman W, Hung MC, Yu D (2009) 14-3-3zeta overexpression defines high risk for breast cancer recurrence and promotes cancer cell survival. Cancer Res 69(8): 3425-3432.
26. Niemantsverdriet M, Wagner K, Visser M, Backendorf C (2008) Cellular functions of 14-3-3 zeta in apoptosis and cell adhesion emphasize its oncogenic character. Oncogene 27(9): 1315-1319.
27. Oue N, Motoshita J, Yokozaki H, Hayashi K, Tahara E, Taniyama K, Matsusaki K, Yasui W (2002) Distinct promoter hypermethylation of p16INK4a, CDH1, and RAR-beta in intestinal, diffuse-adherent, and diffuse-scattered type gastric carcinomas. J Pathol 198(1): 55-59.
28. Park WS, Oh RR, Park JY, Lee SH, Shin MS, Kim YS, Kim SY, Lee HK, Kim PJ, Oh ST, Yoo NJ, Lee JY (1999) Frequent somatic mutations of the beta-catenin gene in intestinal-type gastric cancer. Cancer Res 59(17): 4257-4260.
29. Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55(2): 74-108.
30. Pollack JR, Sorlie T, Perou CM, Rees CA, Jeffrey SS, Lonning PE, Tibshirani R, Botstein D, Borresen-Dale AL, Brown PO (2002) Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors. Proc Natl Acad Sci USA 99(20): 12963-12968.
31. Ralhan R, Desouza LV, Matta A, Chandra Tripathi S, Ghanny S, Dattagupta S, Thakar A, Chauhan SS, Siu KW (2009) iTRAQ-multidimensional liquid chromatography and tandem mass spectrometry-based identification of potential biomarkers of oral epithelial dysplasia and novel networks between inflammation and premalignancy. J Proteome Res 8(1): 300-309.
32. Sharma R, Samantaray S, Shukla NK, Ralhan R (2003) Transcriptional gene expression profile of human esophageal squamous cell carcinoma. Genomics 81(5): 481-488.
33. Shen J, Person MD, Zhu J, Abbruzzese JL, Li D (2004) Protein expression profiles in pancreatic adenocarcinoma compared with normal pancreatic tissue and tissue affected by pancreatitis as detected by two-dimensional gel electrophoresis and mass spectrometry. Cancer Res 64(24): 9018-9026.
34. SobinLH G, Wittekind Ch (2009) International Union Against Cancer (UICC) TNM Classification of Malignant Tumors. 7th edn.Oxford, UKWiley-Blackwell.
35. Tsuda H (2008) Individualization of breast cancer based on histopathological features and molecular alterations. Breast Cancer (Tokyo, Japan) 15(2): 121-132.
36. Tsukamoto Y, Nakada C, Noguchi T, Tanigawa M, Nguyen LT, Uchida T, Hijiya N, Matsuura K, Fujioka T, Seto M, Moriyama M (2010) MicroRNA-375 is downregulated in gastric carcinomas and regulates cell survival by targeting PDK1 and 14-3-3zeta. Cancer Res 70(6): 2339-2349.
37. Uchino S, Tsuda H, Maruyama K, Kinoshita T, Sasako M, Saito T, Kobayashi M, Hirohashi S (1993) Overexpression of c-erbB-2 protein in gastric cancer. Its correlation with long-term survival of patients. Cancer 72(11): 3179-3184.
38. Ushijima T, Sasako M (2004) Focus on gastric cancer. Cancer cell 5(2): 121-125.
39. Wilker E, Yaffe MB (2004) 14-3-3 proteins-a focus on cancer and human disease. J Mol Cell Cardiol 37(3): 633-642.
40. Wulfkuhle JD, Sgroi DC, Krutzsch H, McLean K, McGarvey K, Knowlton M, Chen S, Shu H, Sahin A, Kurek R, Wallwiener D, Merino MJ, Petricoin 3rd EF, Zhao Y, Steeg PS (2002) Proteomics of human breast ductal carcinoma in situ. Cancer Res 62(22): 6740-6749.
41. Yonemura Y, Ninomiya I, Yamaguchi A, Fushida S, Kimura H, Ohoyama S, Miyazaki I, Endou Y, Tanaka M, Sasaki T (1991) Evaluation of immunoreactivity for erbB-2 protein as a marker of poor short term prognosis in gastric cancer. Cancer Res 51(3): 1034-1038.